Achaogen (AKAO) Rating Lowered to Neutral at Mizuho
Mizuho cut shares of Achaogen (NASDAQ:AKAO) from a buy rating to a neutral rating in a research note published on Friday, Marketbeat.com reports.
Several other research firms have also issued reports on AKAO. Stifel Nicolaus lifted their price objective on shares of Achaogen from $14.00 to $22.00 and gave the company a buy rating in a research note on Tuesday, August 7th. BidaskClub lowered shares of Achaogen from a sell rating to a strong sell rating in a research note on Wednesday, July 18th. Zacks Investment Research raised shares of Achaogen from a hold rating to a buy rating and set a $4.75 price objective for the company in a research note on Wednesday, October 10th. Needham & Company LLC lowered shares of Achaogen from a buy rating to a hold rating in a research note on Tuesday, August 7th. Finally, SunTrust Banks reduced their price objective on shares of Achaogen from $16.00 to $10.00 and set a buy rating for the company in a research note on Monday, August 20th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $14.81.
Shares of AKAO stock traded down $0.40 on Friday, hitting $2.25. The company’s stock had a trading volume of 1,656,391 shares, compared to its average volume of 579,029. The company has a current ratio of 3.79, a quick ratio of 3.79 and a debt-to-equity ratio of 0.42. Achaogen has a fifty-two week low of $2.10 and a fifty-two week high of $15.00. The firm has a market cap of $139.24 million, a PE ratio of -0.71 and a beta of 0.67.
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Recommended Story: Rule of 72
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.